Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...

Gene therapy has experienced an increasing number of successful human clinical trials, leading to numerous FDA-approved therapies based on recombinant viruses for rare disease, cancer, and other ...

OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian ...

A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors. This is ...

What is the work you’re leading at KaliVir as CEO? Our goal is to develop viral treatments that can reach and eliminate cancer cells in the body, bringing us closer to a cure for all cancer patients.

VacV Biotherapeutics has taken early steps toward the validation of its systemically deliverable Vaccinia virus, exiting stealth with $3 million to complete preclinical studies of its cancer ...

The oncolytic virus immunotherapy market presents opportunities with three approved therapies, extensive clinical trial pipelines, and innovative research by biotechnology and pharmaceutical companies ...

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that progressed on standard therapy. The next phase of a clinical trial will ...

On April 13, 2026, CG Oncology, Inc. appointed experienced biotechnology finance executive Jim DeTore as its Chief Financial Officer, formalizing a role he had held on an interim basis since November ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of pelareorep, an investigational oncolytic virus ...